Introduction
The anesthetic management of pediatric patients with pulmonary arterial hypertension (PAH) undergoing surgery has received relatively little attention in the literature. Most authors agree that the management of a specific anesthetic technique is as important as the choice of the technique. General anesthesia remains the method of choice for major surgery in these little patients even if several techniques of anesthesia are possible. Although the focus in the literature has been on intraoperative management of pulmonary hypertension, most patients who die in the perioperative period do so several days after surgery. Causes of death include progressive increases in pulmonary vascular resistance (PVR), progressive decreases in myocardial function, and sudden death.
Definition and epidemiology
PAH is defined as the presence of a mean pulmonary artery pressure (PAP) that exceeds 25 mmHg at rest or 30 mmHg during exercise. PAH can be idiopathic or associated with a variety of underlying causes. Pediatric PAH continues to be a considerable problem to the pediatric anesthesiologist even if persistent pulmonary hypertension management of the neonate (PPHN) has seen remarkable advances in recent years [1 ,2 ] . PAH causes are diagnosed as idiopathic in 35% and associated with congenital heart diseases in 50% or with pulmonary diseases in 13%. PPHN occurs in 1-6/1000 live births and is a major cause of morbidity (15-25% neurological handicap) and mortality (20-25%) in the term and near term infant.
Purpose of review
Pediatric pulmonary arterial hypertension (PAH) continues to be a considerable problem to the pediatric anesthesiologist even if its management has seen remarkable advances in recent years. It is important that anesthesiologists caring for children with PAH be aware of the increased risk, understand the pathophysiology of PAH, form an appropriate anesthetic management plan. A review of some of the latest medical advances will provide the reader with a better understanding of the most current anesthetic management options.
Recent findings
The literature reviewed demonstrate sustained clinical and hemodynamic improvement in children with various types of PAH as well as increased survival in patients with idiopathic PAH using current treatment strategies. This article will provide an overview of the current treatment and anesthetic strategies about idiopathic PAH in children over the last years. Summary The first important aspect of anesthetic management is to provide adequate intraoperative anesthesia and analgesia while minimizing increases in pulmonary vascular resistance and myocardial. Depending on the procedure, these goals can be met with the administration of either sedation/analgesia or general anesthesia together with new drugs for PAH treatment in association with a high potential for adverse events. Pathophysiology PPHN is the result of elevated PVR to the point that venous blood is diverted to some degree through fetal channels (i.e., the ductus arteriosus and foramen ovale) into the systemic circulation and bypassing the lungs, resulting in systemic arterial hypoxemia. PPHN can be triggered by a number of events such as meconium aspiration syndrome, respiratory distress syndrome, pneumonia, sepsis, or severe hypoxia. PAH also occurs in children with congenital cardiac lesions with a large left-to-right shunt and high pulmonary blood flow. A potentially fatal complication observed is a pulmonary hypertensive crisis, characterized by a rapid increase in PVR to the point in which PAP exceeds systemic blood pressure (BP). PPHN can be classified into three forms dependent on the likely cause of the pulmonary hypertension:
(1) PPHN associated with pulmonary parenchymal disease such as hyaline membrane disease, meconium aspiration, or transient tachypnea of the newborn as the cause of alveolar hypoxia. The PVR is high in utero but at birth it falls rapidly to near normal levels in the newborn allowing the lungs to establish gas exchange.
The exact pathogenesis of PPHN continues to be undefined although there is a suggestion that this syndrome may be due to an imbalance between vasoconstricting and vasorelaxing factors. Factors which may contribute to this increased PVR include a maladaptation to extrauterine life with a failure of the normal postnatal pulmonary vasodilatation, abnormal muscularization of pulmonary acinar arteries, or an underdevelopment with a decrease both in size and number of pulmonary arterioles. Infants with PPHN have also been shown to have abnormal arginine metabolism and several studies have shown the reduced pulmonary adenosine concentrations in fetal compared with newborn lambs and in patients with pulmonary hypertension (PHT). Pulmonary endothelium and endothelin (ET) [3] , carbone dioxide and hydrogen ion concentration play an important role in PVR, alkalosis produces pulmonary vasodilatation and acidosis results in pulmonary vasoconstriction. Endothelins (ETs) are a family of potent vasoactive modulators, which also mediate smooth muscle cells (SMCs) proliferation in the vascular wall. Endothelin 1 (ET1) is found in the highest concentration and acts on both endothelin A (ET-A) and endothelin B (ET-B) receptors. Endothelin antagonists, both nonspecific blockers of ET-A and ET-B receptors, and specific ET-A antagonists reduce PVR and improve symptoms [4] .
Characteristics of the chest radiograph include prominence of the main pulmonary artery, pruning of the distal pulmonary arteries and cardiomegaly. Echocardiographic findings suggestive of PAH include a tricuspid regurgitation and Doppler velocity greater than 2.5 m.s À1 or an estimated systolic PAP that is more than 50% of systemic systolic arterial BP.
In normal lungs, a large reduction in alveolar oxygen tension will provoke hypoxic pulmonary vasoconstriction (HPV). The relationship between alveolar oxygen tension and PVR is not linear. An increase in PVR occurs only below an alveolar oxygen tension of about 60 mmHg. Furthermore, this response is pH dependent. The HPV response appears to be mainly because of changes in alveolar oxygen tension rather than pulmonary arterial or pulmonary venous oxygen tension. HPV is a fundamental mechanism to instantaneously match pulmonary perfusion to ventilation. The pathophysiological mechanism of HPV is thought to be due to the redox regulation of O 2 -K-sensitive channels of mitochondrial sensors in resistance artery and SMCs. Similarly, the low PO 2 environment favors in-utero pulmonary vasoconstriction, whereas increased alveolar PO 2 secondary to the first few breathes instantaneously vasorelaxes the pulmonary circulation [5] .
Perioperative risk
It is widely accepted that patients with PAH deserve special consideration because they are at increased risk from anesthesia and surgery. In a retrospective study of pediatric and adult patients with congenital heart disease undergoing noncardiac surgery, PAH was a predictor of perioperative morbidity [6] . An interesting study in pediatric patients affected by PAH who underwent cardiac catheterization showed a higher risk of cardiac arrest and death than in children who underwent alternative forms of surgery [7] . A great number of risk factors such as metabolic acidosis, hypoxia, hypoxemia, hypercarbia, and vasoconstriction may cause hemodynamic instability and a significant PVR and PAP increase [8, 9] . There is an important correlation between PVR and PAP, particularly when PVR increases and PAP becomes higher than BP. As a result of these changes and in the absence of right-toleft shunting, a right heart failure together with a decreased cardiac output, bradycardia, dyspnea, and cyanosis may occur [10, 11] .
Clinically, significant pulmonary hypertension is a common finding in newborn infants with congenital diaphragmatic hernia resulting in right-to-left shunting at preductal and postductal level, hypoxemia, and acute right heart failure in those most severely affected. Even in those without clinical manifestations of ductal shunting, cardiac echo studies would suggest that increased PVR and right ventricular pressures are almost a universal Intraoperative management of arterial hypertension Galante 469 finding in this disease, and in some instances, may persist well into the postnatal period. The lung is small and structurally abnormal, and the pulmonary vascular bed is not only reduced in size but also responds abnormally to vasodilators.
Anesthetic management
As many anesthetics exhibit mixed hemodynamic effects and may be unacceptable when used in full anesthetic dosage, it is a useful balanced anesthetic technique in which subanesthetic doses of several drugs were combined to provide general anesthesia.
Benzodiazepines are associated with minimal hemodynamic effects, midazolam appears to be useful as preanesthetic medication without effects on hemodynamic parameters.
In general, sevoflurane is associated with clinical pulmonary vasodilation and is the accepted component of a balanced anesthetic technique in patients with PAH. Volatile agents can lead to dose-dependent depression of cardiac contractility and reduction of systemic vascular resistance (SVR), which may be problematic. Desflurane (but not sevoflurane) inhibits endothelium-dependent relaxation by inhibiting the activity of the adenosine triphosphate-sensitive potassium.
Nitrous oxide has poor hemodynamic effects on infants with PAH. With regard to opioids, remifentanil can cause bradycardia, whereas fentanyl ensures a more stable hemodynamic without changes in cardiac output [12] . A recent study demonstrated that propofol may decrease SVR with serious consequences in patients affected by PAH and right cardiac output failure [13] . Thiopental decreases PVR, but it is a less desirable choice for patients with PAH because it can cause significant myocardial depression and systemic hypotension.
The use of ketamine in children with increased PVR is controversial. In a recent prospective, open label study, the hemodynamic responses to ketamine in children with mean PAP more than 25 mmHg have been evaluated. In the presence of sevoflurane, ketamine did not increase PVR in spontaneously breathing children with severe pulmonary hypertension [14] . Any management strategy should be based upon an attempt to selectively dilate the pulmonary vascular bed thereby increasing pulmonary blood flow and enhancing gas exchange. If this is not possible, the next best option is to try and alter the balance between PVR and SVR preferentially increasing SVR while not altering PVR to the same degree.
An adequate fluid administration up to 30-40 ml/kg intravenous (i.v.) crystalloid fluids is necessary. The arterial pH must be as normal as possible with an arterial carbon dioxide tension of around 4-4.5 kPa (30-35 mmHg) and a high serum bicarbonate resulting in a serum pH of 7.45-7.50. Pulmonary vascular resistance is affected by many aspects of anesthesia technique such as inspired oxygen concentration, acid/base management, ventilation mode, drugs, blood products, cardiopulmonary bypass, pain management, and the stress response. Given the multiple factors involved, it is not surprising that no single anesthetic agent has been shown to be ideal for patients with PAH and that balanced anesthesia is often preferred.
For induction of anesthesia midazolam, fentanyl, a small dose of propofol and/or a low concentration of sevoflurane may be used. Some anesthesiologists include ketamine for induction and maintenance, others prefer to maintain anesthesia with sevoflurane and intermittent fentanyl doses. In our experience and clinical practice we prefer to use a continuous infusion of drugs, particularly for what concern remifentanil instead of fentanyl because of more hemodynamic stability.
Rocuronium and vecuronium have minimal hemodynamics effects so they are preferable but cisatracurium has also demonstrated a good hemodynamic stability.
Epidural regional anesthesia may reduce SVR but availability of new local anesthetics with limited effects on SVR could play an important role even if this topic is controversial in pediatric patients.
Hemodynamic monitoring such as transesophageal Doppler [15] and placement of arterial, and central venous catheters helps to obtain more data together with blood gases, electrolytes, and acid-base balance control.
Treatment
In the case of pulmonary hypertensive crisis it is necessary to administer 100% oxygen (increasing PAO 2 and PaO 2 can decrease PVR), hyperventilate to induce a respiratory alkalosis (PAP is directly related to PaCO 2 ), correct metabolic acidosis (PVR is directly related to H þ concentration), administer pulmonary vasodilators (inhaled nitric oxide is the first choice) [16] , support cardiac output (adequate preload and inotropic support), attenuate noxious stimuli (provide a good analgesia because noxious stimuli can increase PAP and are attenuated by opioids).
The administration of i.v. catecholamines (epinephrine, dopamine, norepinephrine, dobutamine) is necessary if a significant systemic hypotension occurs.
Potential benefits should be expected by combined therapy with inhaled nitric oxide (iNO) and agents that act on the vascular metabolism pathway of the lung such as sildenafil and prostacyclins. This aspect is important in postoperative management.
iNO is effective and rapid as pulmonary vasodilatation. It diffuses into the vascular SMC in which it activates guanylate cyclase that increases cyclic guanosine 3 0 ,5 0 -monophosphate (cGMP) concentrations resulting in vasodilation [17] .
Phosphodiesterase inhibitors (PDE-5) are drugs that block one or more of the five subtypes of the enzyme PDE and prevent the inactivation of cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP). Sildenafil and dipyridamole are PDE-5 inhibitors and are effective as pulmonary vasodilators so they can reduce pulmonary hypertension alone or combined with other vasodilators drugs.
It is an important mediator of pulmonary vasodilatation and is known to play a crucial role during adaptation to extrauterine life. Its effect on vascular tone is mediated by the increment of cAMP levels and is complementary to that of iNO which increases the cGMP levels. Prostacyclin may be delivered into the pulmonary arteries or nebulized. Iloprost and trespostinil are frequently administered but iloprost is supposed to have some advantages over PGI2 because it is not dissolved in an alkaline solution, potentially dangerous for the lung, and has a longer half-life with more prolonged effect [18] .
Adenosine also has been administered to improve oxygenation in infants with PPHN. Atrial naturetic peptide and brain naturetic peptide can be measured to guide therapy because they reflect pressure and volume load of the pulmonary artery.
Magnesium sulfate is a potent vasodilator and hence has the potential to reduce the high pulmonary arterial pressures associated with PPHN. Anywhere, on the basis of the current lack of evidence, the use of magnesium sulfate cannot be recommended in the treatment of PPHN because no eligible trials were found.
Finally, high frequency oscillatory ventilation combined with iNO may be effective in treatment, whereas extracorporeal membrane oxygenation needs to be considered for intractable PAH [19] . In conclusion, intraoperative PAH represents a great risk for pediatric patients, particularly for neonates and infants so anesthesiologists need to perform an accurate anesthetic management. Early treatment of pulmonary hypertensive crisis must be kept in consideration improving alveolar oxygenation, minimizing pulmonary vasoconstriction, and maintaining systemic pressure and perfusion.
